Announced
Financials
Sources
Tags
Biotechnology
Acquisition
biotechnology company
treatment development
Single Bidder
Switzerland
Cross Border
Private
Friendly
clinical stage biotechnology
Pending
Majority
Synopsis
GENFIT, a late-stage biopharmaceutical company, agreed to acquire Versantis, a private Swiss-based clinical stage biotechnology company, for CHF105m. "Versantis has an exciting portfolio that is complementary to GENFIT’s. We are also thrilled to welcome a talented team that has developed a strong scientific expertise in ACLF. We believe that significant synergies exist and that this acquisition will accelerate the development of several promising drug candidates in areas of high unmet needs," Pascal Prigent, GENFIT CEO.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.